A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs PF 06835919 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Feb 2017 Status changed from suspended to completed.
    • 06 Jan 2017 Status changed from active, no longer recruiting to suspended.
    • 21 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top